Overview

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
20 mg or 40 mg of quizartinib will be given to Chinese patients who were just diagnosed with AML. The study drug will be given to them along with standard therapies. The purpose is to find out the highest dose they can stand.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.